Nadia Ali, MD, found several impactful sessions at ASH 2024, highlighting advances in diverse areas of hematology. A standout was a study comparing high-dose and low-dose intravenous iron in pregnancy that demonstrated superior efficiency of and adherence to high-dose iron therapy, prompting Dr Ali to advocate for its implementation in clinical practice.
Dr Ali also valued insights from the Presidential Symposium. This presentation included information on erythropoiesis and novel therapies such as pyruvate kinase activators (eg, etavopivat), which may expand treatments for red blood cell disorders. Additionally, Dr Ali appreciated discussions on artificial intelligence in biomedical research, emphasizing both its potential to mine large datasets and the ethical considerations needed to ensure responsible use.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASH 2024: Key Insights Into Red Blood Cell Disorders - Medscape - Dec 13, 2024.
Comments